Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Veronica Asnaghi, MD, Maria Ballabio, MD, Philippe Jacqmin, Kathy de Graaf, Cristina De Min, MD

Blood (2019) 134 (Supplement_1): 2333.

https://doi.org/10.1182/blood-2019-123995

Published: 2019

Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD

Blood (2018) 132 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2018-99-118465

Published: 2018

Journal Articles

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Sonia Christian, MD, Kelley E. Kozma, DO, Stephanie Barath, Ardaman Shergill, MD, Damiano Rondelli, MD, David Peace, MD, Santosh L. Saraf, MD, Annie Lee Oh, MD, Karen Sweiss, PharmD, Irum Khan, MBBS, Pritesh Patel, MD, Arkadiusz Dudek, MD PhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 5218.

https://doi.org/10.1182/blood-2018-99-111412

Published: 2018

Journal Articles

Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study

Blood (2018) 132 (Supplement 1): 84.

https://doi.org/10.1182/blood-2018-99-115367

Published: 2018

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of REGN3918, a Human Antibody Against Complement Factor C5, in Healthy Volunteers

Jonathan Weyne, MD, Yan Ni, PhD, Richard DelGizzi, PA, MS, Stephen Godin, PhD, Lori Morton, PhD, Srinivasa Prasad, PhD, Andrew J Rankin, PhD, Melissa Simek-Lemos, MPH, ming-Dauh Wang, PhD, Ronda Rippley, PhD, Olivier Harari, MD PhD

Blood (2018) 132 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2018-99-112262

Published: 2018

Journal Articles

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Don M. Benson, Jr., MD PhD, Houston Holmes, MD, Parameswaran Hari, MBBS, MD, Jessica Sachs, MD, Ben Exter, Ann Ranger, PhD, Tooba Cheema, PhD, Iga Sienczylo, BS, Megan M. O'Meara, MD, Django Sussman, PhD, Luke P. Akard, MD

Blood (2018) 132 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2018-99-111729

Published: 2018

Journal Articles

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2577.

https://doi.org/10.1182/blood.V130.Suppl_1.2577.2577

Published: 2017

Journal Articles

Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens

Blood (2016) 128 (22): 1612.

https://doi.org/10.1182/blood.V128.22.1612.1612

Published: 2016

Journal Articles

Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2016) 128 (22): 1067.

https://doi.org/10.1182/blood.V128.22.1067.1067

Published: 2016

Journal Articles

A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Blood (2016) 128 (22): 226.

https://doi.org/10.1182/blood.V128.22.226.226

Published: 2016

Journal Articles

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Blood (2016) 128 (22): 480.

https://doi.org/10.1182/blood.V128.22.480.480

Published: 2016

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

Noopur Raje, Ian Chau, David M. Hyman, Vincent Ribrag, Jean-Yves Blay, Josep Tabernero, Maria Elena Elez-Fernandez, Jürgen S. Wolf, Florin Sirzen, Andrew Yee, Jason Faris, Martin Kaiser, Heather Landau, Jean-Marie Michot, Luisa Veronese, Martina Makrutzki, Susan Francis Lasserre, Igor Puzanov, Jose Baselga

Blood (2015) 126 (23): 4263.

https://doi.org/10.1182/blood.V126.23.4263.4263

Published: 2015

Journal Articles

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

David M. Hyman, MD, Eli Diamond, Vivek Subbiah, MD, Jean-Yves Blay, MD PhD, A. Craig Lockhart, Omar Abdel-Wahab, MD, Florin Sirzen, Maria Luisa Veronese, MD, Susan Frances Laserre, Elena Elez, Jose Baselga, MD PhD

Blood (2014) 124 (21): 635.

https://doi.org/10.1182/blood.V124.21.635.635

Published: 2014

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

Journal Articles

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, MD, Heinz Haverkamp, Andreas Lohri, MD, Stefanie Kreissl, MD, Richard Greil, MD, Jana Markova, MD, Michaela Feuring-Buske, MD, Julia Meissner, MD, Ulrich Dührsen, Nicole Engel, MD, Ulrich Keller, MD, Georg Maschmeyer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2014) 124 (21): 500.

https://doi.org/10.1182/blood.V124.21.500.500

Published: 2014

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

Prasugrel in Children with Sickle Cell Disease: Pharmacokinetic and Pharmacodynamic Characteristics from an Open-Label, Adaptive-Design, Dose-Ranging Study

Lori Styles, MD, Joseph A. Jakubowski, PhD, Darell E. Heiselman, MD, Lori E. Heath, MS, Chunmei Zhou, MS, Charles T. Quinn, MD, MS, Matthew M. Heeney, MD, Rupa Redding-Lallinger, MD, David S. Small, PhD, Brian A. Moser, MS, Kenneth J. Winters, MD

Blood (2012) 120 (21): 3213.

https://doi.org/10.1182/blood.V120.21.3213.3213

Published: 2012

NARROW

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of REGN3918, a Human Antibody Against Complement Factor C5, in Healthy Volunteers

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens

Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia

A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Prasugrel in Children with Sickle Cell Disease: Pharmacokinetic and Pharmacodynamic Characteristics from an Open-Label, Adaptive-Design, Dose-Ranging Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only